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Rottlerin, a Specific Inhibitor of Protein Kinase
C-delta, Impedes Barrier Repair Response by
Increasing Intracellular Free Calcium
Bong K. Ahn1, Se K. Jeong2, Hee S. Kim1, Ki J. Choi3, Jung T. Seo2,4, Eung H. Choi5, Sung K. Ahn5 and
Seung H. Lee1,2
Several signals have been suggested in maintaining skin barrier homeostasis, but epidermal calcium ions are
currently thought to be a main signaling factor. It is not clear, however, exactly how an intracellular calcium level
decreases in response to the loss of an extracellular calcium gradient. In this study, we investigated the effects
of several broad-type and isozyme-specific protein kinase C (PKC) inhibitors on epidermal permeability barrier
recovery. Topical application of chelerythrine chloride, a broad-type PKC inhibitor, and rottlerin, a PKCd-specific
inhibitor, significantly impeded the barrier recovery rate at 3 and 6 hours after barrier disruption. A significant
decrease in the number and secretion of lamellar bodies was also observed at the inhibitor-treated site. Calcium
ion-capture cytochemistry showed that the epidermal calcium gradient was rapidly reformed in inhibitor-
treated skin, though recovery of the corresponding barrier function was not observed. In cultured keratinocytes
treated with either inhibitor, increased intracellular calcium did not return to the baseline concentration
after extracellular calcium decreased. These results suggest that PKC inhibitors, especially a PKCd-specific
inhibitor, delay barrier recovery by affecting the intracellular calcium concentration after a loss of the
extracellular calcium gradient. Furthermore, PKCd is important in controlling a decrease in intracellular calcium
concentration.
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INTRODUCTION
The outer sheath of the skin, the stratum corneum (SC),
not only defends against the entry of microorganisms but
also protects against excessive water loss. Disruption of this
permeability barrier has been reported to occur in several
inflammatory dermatoses, including allergic contact derma-
titis (Hachem et al., 2001; Held et al., 2001), hand dermatitis
(Agner, 1992), hypertrophic scar and keloid (Suetake et al.,
1996), atopic dermatitis (Werner and Lindberg, 1985;
Berardesca et al., 1990; Watanabe et al., 1991; Loden
et al., 1992), and psoriasis (Tagami and Yoshikuni, 1985;
Ghadially et al., 1996). The permeability barrier can also
be artificially disrupted by topical treatment with organic
solvents, tape stripping, or detergents (Feingold, 1997).
Regardless of the manner of barrier disruption, the barrier
repair response leads to a restoration of normal barrier func-
tion. Immediately after barrier disruption, all of the lamellar
bodies (LBs) in the outermost granular cells are secreted
(Menon et al., 1992b), and an increase in both cholesterol
and fatty acid synthesis occurs. In contrast, a delayed
increase in ceramide synthesis (Holleran et al., 1991) as well
as a stimulation of epidermal b-glucocerebrosidase (Holleran
et al., 1994) and DNA synthesis (Proksch et al., 1991) are
associated with the late phase of barrier recovery. To
address this issue, it is crucial to know the intracellular
signals involved in inducing the above-mentioned biological
responses after cutaneous barrier disruption.
Calcium ions act as a major regulator in keratinocyte
differentiation and proliferation, and epidermal calcium
ions are thought to be a main signaling factor in maintaining
skin barrier homeostasis. It is unclear, however, what role
losing the extracellular calcium gradient plays in the
barrier recovery response after cutaneous barrier disruption.
In addition, the mechanism by which the intracellular free
calcium level concentration ([Ca2þ ]i) decreases in response
to the loss of the extracellular calcium gradient is also
unclear.
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We studied the roles of protein kinase C (PKC) inhi-
bitors and [Ca2þ ]i regulation in barrier repair after acute
barrier disruption. By measuring transepidermal water loss
(TEWL) and using morphological studies, we found reduced
barrier recovery with PKC inhibition, particularly PKCd-
specific inhibition. The [Ca2þ ]i measurements suggest that
this reduced barrier recovery is due to a lack of intracellular
calcium response to an extracellular calcium change.
RESULTS
Barrier recovery rate of broad-type PKC inhibitors
Repeated tape stripping was carried out on both sides of
the flank of male hairless mice. Chelerythrine chloride, a
broad-type PKC inhibitor solution of appropriate concentra-
tion, and vehicle were applied to the barrier-disrupted site for
10 minutes. The stripped and treated skin showed signi-
ficantly delayed barrier recovery when compared to vehicle-
treated skin at 3 and 6 hours. The percent TEWL recovery
decreased in a dose-dependent manner (Figure 1a). Another
broad-type PKC inhibitor, calphostin C, also significantly
delayed barrier recovery at 3 and 6 hours (Figure 1b).
Barrier recovery rate of isoenzyme-specific PKC inhibitors
We performed additional barrier recovery rate experiments
to identify which specific PKC inhibitor impeded the barrier
recovery response. The stripped skin treated with rottlerin,
a PKCd-specific inhibitor, showed a significantly delayed
barrier recovery as compared to vehicle-treated skin at
3 hours. The percent TEWL recovery of rottlerin-treated skin
decreased in a dose-dependent manner (Figure 2a). Other
PKC isoform-specific inhibitors, Go¨6976 (PKCa) and Mry
(PKC zeta; pseudosubstrate sequence from human PKCz),
did not show significantly delayed barrier recovery at 3 and
6 hours (Figure 2b).
Formation of SC lipid lamellae and secretion of LB
We used Nile red staining and quantitative electron micro-
scopy to assess changes in LB secretion and lipid deposition
in the SC. The vehicle-treated skin showed an intense red
staining in the Malphigian layer and the SC at 3 and 6 hours
(Figure 3v). The chelerythrine chloride-treated skin showed
very weak staining in the epidermis at 3 hours after barrier
disruption and delayed staining at 6 hours (Figure 3c).
Rottlerin-treated skin showed staining similar to the chelery-
thrine chloride treatment (Figure 3r). Go¨6976-treated skin
showed an intense red staining in the epidermis, much like
vehicle-treated skin (Figure 3g).
Although there was acute barrier disruption, electron
micrographs showed that the secretion of LB between the
SC and stratum granulosum (SG; secreted) was significantly
decreased. Considerable numbers of LB remained in the
upper layers of the SG (unsecreted) following chelerythrine
chloride treatment (Figure 4c). Similar findings were seen
in the rottlerin-treated skin. Rottlerin treatment also showed
a decrease in the number of LBs between the SC and SG, and
many LBs remained in the upper layers of the SG at 3 hours
(Figure 4r). Treatment with the PKC-a-specific inhibitor,
Go¨6976, showed normal secretion of LB to the SC and
fewer LBs remained within the SG (Figure 4g), similar to
vehicle-only treatment (Figure 4v). At 30 minutes after
barrier disruption, LB secretion between the SC and SG in
chelerythrine chloride- and rottlerin-treated skin was signi-
ficantly lower than that in vehicle-treated skin. Furthermore,
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Figure 1. Broad-type PKC inhibitors delay the barrier recovery. (a) Topical
application of chelerythrine chloride, a broad-type PKC inhibitor, delayed the
barrier recovery rate in a dose-dependent manner. (b) Another broad-type
PKC inhibitor, calphostin C, also significantly delayed barrier recovery at
3 and 6 hours (*Po0.05, **Po0.01).
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Figure 2. PKCd-specific inhibitor delays the barrier recovery. The stripped
skin treated with rottlerin showed significantly delayed barrier recovery
as compared to vehicle-treated skin at 3 hours. (a) The percent TEWL recovery
in rottlerin-treated skin was decreased in a dose-dependent manner.
(b) Other PKC isoform-specific inhibitors, Go¨6976 (PKCa) and Mry (PKC-zeta;
pseudosubstrate sequence from human PKCz), did not show significantly
delayed barrier recovery at 3 and 6 hours (**Po0.01).
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Figure 3. Broad-type and d-specific PKC inhibitors impede the neutral lipid
deposition during barrier recovery. Neutral lipid deposition in the epidermis
was examined by Nile red staining. The upper line denotes 3 hours after
barrier disruption and the lower line denotes 6 hours after barrier disruption.
The vehicle-treated skin showed an intense red staining in the Malphigian
layer and SC at 3 and 6 hours (v). The chelerythrine chloride-treated skin
showed very weak staining in the epidermis at 3 hours and delayed staining at
6 hours (c). Similar weak and delayed staining was seen in rottlerin-treated
skin (r). Go¨6976-treated skin showed an intense red staining in the epidermis,
similar to vehicle-treated skin (g).
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in the chelerythrine chloride and rottlerin treatments, the
number of LBs within the SG was significantly higher than in
vehicle-treated skin (Table 1).
Effect of PKC inhibitors on epidermal calcium gradient
By using ultrastructural calcium capture cytochemistry, we
observed changes in the epidermal calcium gradient. A
progressive increase in the number of calcium precipi-
tates, from the basal layers toward the SG, was observed in
vehicle-treated skin (Figure 5a–c). A loss of the epidermal
calcium gradient was observed at 3 hours after barrier
disruption (Figure 5d). The topical application of the
chelerythrine chloride resulted in increased calcium pre-
cipitates in the upper layer of the SG, though a nearly normal
epidermal calcium gradient was observed at 3 hours after
barrier disruption (Figure 5e). Similar findings were seen in
the rottlerin-treated skin. Rottlerin-treated skin also showed
an epidermal calcium gradient at 3 hours after barrier
disruption (Figure 5, ROT-3 hours). Go¨6976-treated skin
showed a normal loss of calcium gradient at 3 hours, much
like vehicle-treated skin (Figure 5, GO-3 hours). To determine
whether the Ca2þ gradient was abrogated and then returned,
or not abrogated at all after barrier disruption and rottlerin
treatment, we observed a time course at 30 minutes and
1 hour. At 30 minutes, rottlerin-treated skin showed an
abrogated epidermal calcium gradient. Although TEWL was
still high and barrier recovery was not complete at 1 and
3 hours (Figure 2), the epidermal calcium gradient was
rapidly reformed (Figure 5, ROT). In the case of Go¨6976-
treated skin, a well-formed epidermal calcium gradient was
not seen at 30 minutes, 1, or 3 hours (Figure 5, GO).
The effects of broad-type of PKC inhibitor on [Ca2þ ]i
To define the effect of PKC inhibitors in vitro, we examined
the [Ca2þ ]i level by using Fura-2. As shown in Figure 6a,
in untreated control keratinocytes, the increase in extra-
cellular free calcium level ([Ca2þ ]o) induced an increase
in [Ca2þ ]i. The elevated [Ca
2þ ]i returned to baseline when
[Ca2þ ]o was decreased (Figure 6a). To test the effect of
the PKC inhibitor, we treated keratinocytes with 5 mM
chelerythrine chloride. In contrast to the untreated keratino-
cytes, chelerythrine chloride treatment caused a marked
increase in [Ca2þ ]i with increasing [Ca
2þ ]o. Furthermore,
the elevated [Ca2þ ]i did not return to the baseline level after
lowering [Ca2þ ]o (Figure 6b). Chelerythrine chloride inhib-
ited the decreasing [Ca2þ ]i in response to an extracellular
calcium change.
Effects of PKC isoenzyme-specific inhibitors on [Ca2þ ]i
To define the effect of PKC isoenzyme-specific inhibitors
in vitro, we examined [Ca2þ ]i levels by using Fura-2. To test
the effect of the PKC-a-specific inhibitor, we treated keratino-
cytes with 0.5 mM Go¨6976. As shown in Figure 6c, Go¨6976-
treated keratinocytes showed that an increase in [Ca2þ ]o
induced an increase in [Ca2þ ]i, which tended to return to
baseline when [Ca2þ ]o decreased (Figure 6a). In contrast to
the untreated control and Go¨6976-treated keratinocytes,
rottlerin-treated keratinocytes showed a more marked in-
crease in [Ca2þ ]i when [Ca
2þ ]o increased, which did not
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Figure 4. Broad-type and d-specific PKC inhibitors impede the LB secretion.
OsO4 post-fixation was used for LB counting. Vehicle-treated skin showed
that LBs were actively secreted to the SC and LBs within the SG were
decreased or exhausted (v), as is normally seen in untreated skin. Although
there was acute barrier disruption, electron micrographs showed that the
secretion of LB between the SC and the SG was significantly decreased, and
considerable numbers of LB remained in the upper layers of the SG in
chelerythrine chloride-treated skin (c). Similar findings were seen in rottlerin-
treated skin. Rottlerin-treated skin also showed a decrease in the number of
LBs between the SC and SG. Many LBs remained in the upper layers of the SG
3 hours after barrier disruption (r). The PKC-a-specific inhibitor, Go¨6976,
treated skin showed normal secretion of LB to the SC and fewer LBs remained
in the SG (g) (OsO4, bar¼ 1 mm).
Table 1. Comparison of the number of LBs in the electron microscopic pictures
Chelerythrine
chloride-treated skin
Rottlerin-treated
skin
Vehicle-treated
skin
Chelerythrine
vs vehicle
Rottlerin
vs vehicle
Number of LBs between
the SC and SG (secreted LB)
21 10 32 8 28 19 31 28 15 18 3 9 1 6 7 Po0.05 Po0.05
Total number (mean7SD) 97 (19.8710.6) 133 (22.276.2) 26 (5.273.2)
Number of LBs within
the SG (unsecreted LB)
3 9 7 2 4 5 2 6 1 2 3 16 12 10 4 Po0.05 Po0.05
Total number (mean7SD) 25 (5.072.9) 16 (3.272.2) 55 (9.075.5)
LB, lamellar body; SC, stratum corneum; SG, stratum granulosum.
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return to the baseline level when [Ca2þ ]o was decreased
(Figure 6). Among the several isoform-specific PKC inhibitors,
rottlerin, a PKCd-specific inhibitor, inhibited the [Ca2þ ]i
response to extracellular calcium change.
DISCUSSION
Several signals have been suggested in mediating the homeo-
static processes that take place in cutaneous barrier disrup-
tion response. As barrier disruption is always accompanied
by an increase in TEWL, it is reasonable to speculate that
this water loss and the consequent change in keratinocyte
tonicity induce the stimulation. The fact that occlusion can
block the lipid and DNA synthesis responses to barrier
disruption suggests that TEWL is also a regulatory signal in
barrier homeostasis. But, since immediately exposing barrier-
perturbed skin to isotonic, hypertonic, or hypotonic external
solutions results in normal barrier recovery, water move-
ment is not considered a major signal in barrier homeostatic
responses (Lee et al., 1992).
In addition to skin barrier homeostasis, calcium ions act
as a major regulator in keratinocyte differentiation and proli-
feration. The epidermis has a calcium gradient, with the
highest levels in the SG and lowest levels in the basal cell
layer (Menon et al., 1985a), which is very important for both
permeability barrier homeostasis and epidermal differen-
tiation. The Ca2þ gradient disappears after acute barrier
disruption, and reappears in parallel with barrier restitution
(Menon et al., 1992a; Mao-Qiang et al., 1997; Mauro et al.,
1998). In a previous study, it was shown that immersion of
barrier-disrupted skin into a calcium ion-containing solution
significantly delayed barrier recovery. In addition, if potas-
sium and, to a lesser extent, magnesium and phosphorous
ROT–30 minutes ROT–1 hour ROT– 3 hours
GO–30 minutes GO–1 hour GO–3 hours
a b c
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e
Figure 5. Although there was barrier disruption and incomplete barrier
recovery, broad-type and d-specific PKC inhibitor-treated skin showed the
well-formed epidermal calcium gradient. (a–c) Visualization of epidermal
calcium gradient by ultrastructural calcium capture cytochemistry shows a
progressive increase in the number of calcium precipitates from the basal
layers toward the SG in vehicle-treated skin. (d) A loss of the epidermal
calcium gradient was observed at 3 hours after barrier disruption. (e) The
topical application of the chelerythrine chloride resulted in an increase in
calcium precipitates in the upper layer of SG, though a nearly normal
epidermal calcium gradient was observed at 3 hours after barrier disruption
(bar¼ 3 mm). In case of isoform-specific PKC inhibitors, we observed a time
course at 30 minutes and 1 hour. At 30 minutes, the rottlerin-treated skin
showed abrogated an epidermal calcium gradient, but the gradient was
rapidly reformed at 1 and 3 hours (ROT 30 minutes, 1, 3 hours). In the case of
Go¨6976-treated skin, a well-formed epidermal calcium gradient was not seen
at 30 minutes, 1 or 3 hours (GO 30 minutes, 1, 3 hours) (bar¼2 mm).
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Figure 6. Broad-type and delta-specific PKC inhibitors impede the decrease
of [Ca2þ ]i. An increase of [Ca
2þ ]o, due to moving from 0.15 to 1.5 mM N-2-
hydroxyethylpiperazine-N0-2-ethanesulfonic acid-buffered Ca2þ solution,
induced an increase in [Ca2þ ]i. (a) The elevated [Ca
2þ ]i returned to baseline
with a reduction in [Ca2þ ]o to 0.15 mM. In the case of chelerythrine chloride
(5 mM)-treated keratinocytes, there was slight increase in the [Ca2þ ]i baseline.
(b) The [Ca2þ ]o increase from 0.15 to 1.5 mM induced a [Ca
2þ ]i increase that
did not return to baseline after decreasing the [Ca2þ ]o to 0.15 mM. (c) Go¨6976
(0.5 mM)-treated keratinocytes showed a [Ca2þ ]i change similar to that seen in
untreated keratinocytes. (d) In rottlerin (10mM)-treated keratinocytes, [Ca2þ ]i
did not return to baseline and remained elevated, despite a decrease in
[Ca2þ ]o to 0.15 mM. The data in this graph represent the mean of 10 cells.
www.jidonline.org 1351
BK Ahn et al.
The PKCd-Specific Inhibitor Impedes Barrier Repair Response
ions are present in the bathing solution, barrier recovery is
also impeded. Moreover, calcium and potassium ions
together appear to be synergistic in inhibiting barrier recovery
(Lee et al., 1992). The central role of calcium ions in skin
barrier homeostasis was demonstrated by the manipulation
of LB secretion through changing the epidermal calcium
gradient and without significantly changing TEWL, by ionto-
phoresis or sonophoresis. These studies suggest that changes
in calcium ion concentration in the SG can directly transduce
the homeostatic signals for barrier repair, even without a
change in permeability barrier function (Lee et al., 1998a).
In most of the cases, however, the role of the extracellular
calcium gradient and the decrease in [Ca2þ ]i in cutaneous
barrier homeostasis were treated separately. Increased water
movement, followed by passive calcium displacement out-
ward, could explain the extracellular calcium ion loss from
epidermis. Mauro et al. (1998) recorded changed calcium
ion concentrations in the outer epidermis from 460757 to
128714 mg/kg immediately after barrier disruption. Most
of the calcium ions contributing to this measurement are
localized in the epidermal extracellular space. As there is
a substantial and tightly controlled difference between
intracellular free calcium ion and extracellular calcium ion
concentrations, even with a significant decrease, the extra-
cellular calcium level is still much higher than [Ca2þ ]i
(Mauro, 2003). The precise mechanism of [Ca2þ ]i decrease
in response to a loss of the extracellular calcium gradient is
still not clear.
In this study, we investigated the effects of PKC inhibitors
on barrier recovery. Collectively, our results can be explained
as follows. Broad-type PKC inhibitors and a PKCd-specific
inhibitor reduced barrier recovery by inhibiting the intra-
cellular Ca2þ response to loss of the extracellular Ca2þ
gradient. While nearly all results were similar between these
two inhibitors, as seen in Figure 6b and d, the calcium trace
of chelerythrine chloride is somewhat different from that of
rottlerin. The calcium trace of chelerythrine chloride-treated
keratinocytes showed an unstable and increasing baseline.
When the extracellular calcium level was increased, the
calcium trace increase in chelerythrine chloride was slower
than in rottlerin. As this type of calcium trace can be seen
in an unregulated calcium influx such as a cytotoxic effect,
we carried out a cytotoxicity study for chelerythrine chloride,
rottlerin, and Go¨6976 with alamar blue. This study showed
less than 10% cytotoxicity in the chelerythrine chloride-
treated cultured cells. Rottlerin and Go¨6976 did not show
any cytotoxicity at all. Although the chelerythrine chloride
calcium trace showed an increasing baseline and slower
[Ca2þ ]i response, we believe these results are secondary
effects of weak cytotoxicity, and mask the typical calcium
curve (Figure 6d). As chelerythrine chloride is a broad-type
PKC inhibitor, these results may be due to blocking by
PKC isoenzymes other than d. Regardless, the chelerythrine
chloride results are not totally insignificant.
These results suggest that, among the PKC isoenzymes
extant in keratinocytes, PKCd may be associated with this
phenomenon. It is also possible, however, that PKC inhibitors
increase [Ca2þ ]i not only by inhibiting the intracellular Ca
2þ
response to decreased [Ca2þ ]o, but also by affecting calcium
influx through the calcium channel. Conversely, these
findings indirectly suggest that PKC is involved in barrier
recovery by keeping [Ca2þ ]i elevated.
At this point, the role of PKC in keratinocyte differentiation
is well known, but its role in barrier recovery response is not.
Only Murata et al. (2000) were able to demonstrate that both
serine-palmitoyl transferase and glucosylceramide synthetase
expression are upregulated by a PKC-dependent mechanism
in cultured human keratinocytes. Also, no reports on the
mechanism explain the calcium elevation effect that takes
place in keratinocytes when the barrier is disrupted. Similar
[Ca2þ ]i regulation is seen in other cells, namely granulosa
cells. Basic fibroblast growth factor prevents granulosa cell
apoptosis by decreasing [Ca2þ ]i (Lynch et al., 2000). Peluso
et al. (2001) elucidated the mechanism through which basic
fibroblast growth factor-activated PKCd regulates [Ca2þ ]i
within a physiological range by stimulating calcium efflux.
They proposed that activated PKC functions to serine/
threonine phosphorylate various molecular targets that may
include calcium efflux regulators, such as plasma membrane
calcium-adenosine triphosphatase. As has been shown in
other cell types, D12-O-tetradecanoylphorbol-13-acetate-
dependent phosphorylation of plasma membrane calcium-
adenosine triphosphatase enhances the rate of calcium
efflux, thereby maintaining calcium homeostasis (Garcia
and Strehler, 1999). Studies have found, with results similar
to ours, that the plasma membrane calcium-adenosine
triphosphatase pump is localized to the plasma membrane
and its activity is influenced by PKC (Blaustein and Lederer,
1999; Philipson and Nicoll, 2000; Therien and Blostein,
2000). PKCd is the only PKC isotype that is expressed by
granulosa cell. The existence of PKCa, d, e, Z, and z in
keratinocytes is well documented (Dlugosz et al., 1992;
Fischer et al., 1993; Denning et al., 1995; Lee et al., 1998b),
and other PKC isoforms (PKCb, g, and m) have also been
found in various keratinocytes (Fischer et al., 1993; Fisher
et al., 1993; Rennecke et al., 1996). Among the normal
keratinocyte PKC isoenzymes, we studied a, d, and z because
these are representative enzymes of conventional, novel, and
atypical PKCs, respectively. PKCd, the novel PKC isoform, is
diacylglycerol sensitive but calcium insensitive. Therefore,
we feel that PKCd may be a more likely candidate for
calcium regulation than isoenzymes subjected to skewed
[Ca2þ ] following acute barrier disruption. In fact, our
proposed mechanism is missing a link between the extra-
cellular calcium decrease and PKC activation. A protein such
as CaR, which functions in the case of elevated extracellular
calcium level, could fill this gap. We found that there was an
increase of diacylglycerol, an endogenous PKC activator,
when the barrier is disrupted (data not shown), but we
could not find a signal or receptor to link the decrease
of extracellular calcium to diacylglycerol elevation. Our
suggested mechanism of calcium regulation by PKC is shown
in Figure 7. When the permeability barrier is disrupted,
an increase in transepidermal water loss is followed by an
extracellular calcium decrease in the outer epidermis. This
extracellular calcium loss leads to the transduction of an
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unknown signal in keratinocytes. This signal may increase
the level of diacylglycerol and activate PKC, which in turn
regulates the [Ca2þ ]i decrease by stimulating calcium efflux.
Thus, a variety of responses for barrier repair are induced.
Future studies will be needed to test this hypothesis.
MATERIALS AND METHODS
Animals
Male mice that were 8–12 weeks old and hairless were purchased
from the animal laboratory of Yonsei University and used in this
study. The Institutional Review Board at Yonsei University College of
Medicine approved the use of mice, and the Medical Ethical
Committee of the Yonsei University College of Medicine approved
all described studies.
Reagents
The polyethylene glycol (Mw 300) and ethanol used as vehicles
were purchased from Sigma Chemical (St Louis, MO). The broad-
type PKC inhibitors, calphostin C and chelerythrine chloride, were
purchased from Calbiochem (San Diego, CA). Other PKC iso-
enzyme-specific inhibitors were purchased from Biomol (Plymouth
meeting, PA).
Barrier disruption
The epidermal permeability barrier of hairless male mice, 8–12
weeks old, was broken by tape stripping. The procedure was
terminated when the TEWL reached 40 mg/cm2/hour. A normal
TEWL is less than 0.2 mg/cm2/hour. TEWL was measured with a
TM210 (Courage & Khazaka, Cologne, Germany). TEWL measure-
ments were taken at the treatment sites 30 minutes, 1, 3, and 6 hours
after barrier disruption. The barrier recovery results are expressed
as percent recovery calculated by the following formula: (TEWL
immediately after barrier disruption – TEWL at indicated time point)/
(TEWL immediately after barrier disruption–baseline TEWL) 100%.
Topical application of PKC inhibitor
Chelerythrine chloride and other isotype-specific inhibitors of PKC
were dissolved in DW/polyethylene glycol/ethanol (1:3:1 vol/vol). In
all, 10 ml of each inhibitor solution was applied to a 3 cm 1 cm area
of barrier disrupted mouse skin immediately after barrier disruption
for 10 minutes. Neither the mixture nor the vehicle was irritating
under the conditions of this experiment.
Electron microscopic examination
OsO4 post-fixation. OsO4 post-fixation was used to count the
layers of SC and the number of LB, and RuO4 post-fixation was used
to observe LB secretion and the lipid structure of the SC intercellular
space. Biopsy specimens were immediately cut into 1-mm3 pieces
and fixed in modified Karnovsky’s fixative overnight, washed in
0.1 M cacodylate buffer, and post-fixed in 1% OsO4 in 0.1 M
cacodylate buffer for 1 hour. After rinsing in buffer, samples were
dehydrated in graded ethanol solutions, and embedded in an
epon–epoxy mixture. Ultrathin sections (60–80 nm) were examined
in a transmission electron microscope (H-7600, Hitachi, Japan) after
further contrasting with uranyl acetate-lead citrate. We compared
the specimens of chelerythrine chloride-treated skin with that of the
control vehicle-treated skin at 30 minutes after barrier disruption.
We took electron microscopy pictures from each specimen and the
number of SC layers and LBs per picture (magnification  25,000)
were counted. We placed five 1 1 inch square grids at the junction
of the SC and SG and counted within them to assess LB secretion.
We placed the same grids at the SG for assessing the number of
unsecreted LB.
Calcium-capture cytochemistry. Biopsy specimens were imme-
diately cut into small pieces (0.5 mm3) in a drop of ice-cold fixative
(2% glutaraldehyde, 2% formaldehyde, 90 mM potassium oxalate,
and 1.4% sucrose) and fixed overnight on ice (Menon et al., 1985b).
The fixative was removed and the samples were post-fixed in
osmium tetroxide/potassium pyroantimonate for 2 hours on ice
and washed for 10 minutes in ice-cold distilled water (pH 10). The
samples were then dehydrated in a graded ethanol series, and
embedded in epon–epoxy resin. Ultrathin sections (60–80 nm) were
examined in a transmission electron microscope (H-7600, Hitachi,
Japan). Each section was incubated with EDTA as a control.
Cell culture
Skin was obtained from newborn mice and treated with 0.5% trypsin
in Hank’s balanced salt solution solution (pH 7.4) overnight at 41C.
The epidermis was then mechanically separated from the dermis,
and epidermal cells were released in Hank’s balanced salt solution
with 0.05% DNase and 20% fetal bovine serum. After washing, the
keratinocytes were seeded in a collagen-coated dish at 1 106 cells
with keratinocyte serum-free medium. The calcium concentration in
the medium was adjusted by addition of 0.3 M CaCl2 stock. Cells
were cultured in medium with 0.05 mM calcium to maintain a
proliferating population of basal cells. Terminal differentiation was
induced by exposing the culture to medium containing 2 mM
calcium for 24 hours.
Measurement of [Ca2þ ]i
Differentiated cultured hairless mouse keratinocytes were loaded
with 4mM Fura-2 AM (Kd¼ 224 nM) in 25 mM N-2-hydroxyethylpi-
perazine-N0-2-ethanesulfonic acid buffer (130 mM sodium chloride,
3 mM potassium chloride, 2 mM magnesium chloride, 1 mg/ml
pyruvate, 10 mM glucose, and 0.03 mM calcium chloride; pH 7.4)
for 30 minutes. Cells were then washed and resuspended in buffer
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Figure 7. The suggested mechanism of intracellular calcium regulation by
PKC.
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twice. Fluorescence was recorded with a spectrofluorometer (Photon
Technology International, Brunswick, NJ), coupled to a microscope
(Nikon, Tokyo, Japan) using the fluorescence ratios at 340 and
380 nm (F340/F380) excitation and emission wavelengths, respec-
tively. Each sample was calibrated by the addition of ionomycin
(10 mM final concentration) (Fmax), followed by 0.1% Triton X-100
and 10 mM EGTA/Tris (pH 8.3; Fmin). [Ca
2þ ]i was calculated with the
following formula:
½Ca2þi ¼ KDSf2=Sb2 ðR  RminÞ=ðRmax  RÞ½ 
where KD is the dissociation constant of Fura-2; R the fluorescence
ratio measured at l340/330; Rmin the fluorescence ratio measured at
PC12 cells after 2.5 mM EGTA treatment; Rmax the fluorescence ratio
measured at PC12 cells after 25 mM ionomycin treatment; Sf2 the
fluorescence intensity of l380 at Rmin; and Sb2 the fluorescence
intensity of l380 at Rmax.
Measurement of the cytotoxicity
In this experiment, cytotoxicity of the PKC inhibitors was measured
with the alamar blueTM method. Human immortalized keratinocyte
HaCaT cells were used. Cells were seeded in 96-well plates (1 104
cells/well). When the cells were 80% confluent, the media was
removed and the cells were washed with Ca2þ , Mg2þ -free PBS
(pH 7.4) solution. After washing, cells were added to each well and
incubated in 175ml of a tested inhibitor for 1 hour. After incubation,
solutions were removed and cells were washed with PBS. Each well
was incubated in 175ml of alamar blueTM solution for 24 hours. After
incubation, alamar blueTM reduction was determined by measuring
absorbance at 570 and 600 nm with a microplate reader (Spectramax
340PC, Molecular Device, Sunnywale, CA). A standard curve was
obtained for the alamar blueTM reduction by HaCaT cells and the
number of viable cells was calculated.
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